Lane, Wendy

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study

Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 243

Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study

Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 234

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

Lane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 206

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

Hirsch, I. B., Bode, B. W., Garg, S., Lane, W. S., Sussman, A., Hu, P., Santiago, O. M., Kolaczynski, J. W., & for the Insulin Aspart CSII/MDI Comparison Study Group (2005) · Diabetes Care

Diabetes Management and ResearchDiabetes Management and Education

Cited by 197